Ustekinumab for Crohn ' s Disease: Long-term Efficacy, Safety Ustekinumab for Crohn ' s Disease: Long-term Efficacy, Safety
This study assessed long-term extension data of ustekinumab for Crohn ' s disease, demonstrating the maintenance of response and remission and continued safety through 92 weeks.Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
More News: Crohn's Disease | Drugs & Pharmacology | Gastroenterology | Health | Inflammatory Bowel Disease | Stelara | Study